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OBJECTIVE: The JAK2 46/1 haplotype has recently been described as a major contributing factor to the
development of myeloproliferative neoplasm, whether positive or negative for the JAK2 V617F mutation. The G
allele, identified by a single-nucleotide polymorphism known as JAK2 rs10974944, is part of the JAK2 46/1
haplotype. The aim of this study was to verify the association between the presence of the G allele and the
development of BCR-ABL-negative chronic myeloproliferative neoplasms in our population.
METHODS: Blood and oral mucosa swab samples were obtained from 56 patients of two local Brazilian
hospitals who had previously been diagnosed with BCR-ABL-negative chronic myeloproliferative neoplasms.
Blood samples from 90 local blood donors were used as controls. The presence of the G allele was assessed using
a PCR-RFLP assay after extracting DNA from the samples.
RESULTS: The presence of the G allele was strongly associated with the presence of BCR-ABL-negative chronic
myeloproliferative neoplasms (p=0.0001; OR=2.674; 95% CI = 1.63024.385) in the studied population.
CONCLUSION: In agreement with previous reports, the JAK2 46/1 haplotype, represented in this study by the
presence of the G allele, is an important predisposing factor in the oncogenetic development of these
neoplasms in our population.
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& INTRODUCTION
Chronic myeloproliferative neoplasms (cMPNs) are dis-
orders that are characterized by the clonal proliferation of a
single hematopoietic stem cell and result in increased
peripheral blood counts of mature cells; they include
chronic myeloid leukemia (CML), polycythemia vera (PV),
essential thrombocythemia (ET) and primary myelofibrosis
(MF) (1). The JAK2 V617F mutation was identified in more
than 95% of PV patients and in approximately half of the
patients with ET and MF but was not observed in healthy
individuals (2-6). Consequently, JAK2 V617F mutation
screening became a cornerstone in the molecular diagnostic
approach for cMPN (1,7).
Even before identifying a common mutation associated
with the development of cMPN, family clusters of patients
sharing various types of these disorders had already been
identified (8). Landgren et al. (9) studied the risk of PV, ET
and MF development among the first-degree relatives of
patients who had been previously diagnosed with cMPN.
First-degree relatives were observed to have a five to seven
times greater risk of developing cMPN, particularly in
certain probands, suggesting that family members may
share some of the oncogenes involved in myeloproliferative
disorders.
Pardanani et al. (10) studied the genetic factors that could
contribute to the phenotypic diversity of cMPN. The authors
observed that some JAK2 gene SNPs and haplotypes
occurred more frequently in PV patients than in ET or MF
patients. They suggested that individual genetic factors
could contribute to the diverse phenotypic presentation of
cMPN.
Following the above findings, Jones et al. (11) analyzed
several JAK2 SNPs. Considering uniparental disomy as the
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main cause of JAK2 V617F mutation homozygosity, the
authors concluded that the JAK2 V617F mutation does not
occur randomly but rather in a specific JAK2 gene
haplotype. A comparison of JAK2 gene SNPs led to the
identification of 92 different haplotypes. Two of them,
referenced together as the 46/1 haplotype, were more
frequently observed in patients carrying the JAK2 V617F
mutation than in the general population.
Using genomic array techniques, Kilpivaara et al. (12)
searched for SNPs that could predispose an individual to
develop cMPN or that might act as phenotypic modifiers in
these diseases. The JAK2 G allele, characterized by the
presence of the rs10974944 SNP, occurred more frequently
in PV than in ET patients. It was also more frequently
observed in cMPN patients than in the general population.
The C allele, characterized by the absence of the rs10974944
SNP, was considered to be the common allele that was most
frequently observed in the general population. The G allele
was also strongly associated with the JAK2 V617F mutation,
with both occurring more frequently on the cis strand.
The aim of this study is to analyze the possible association
between the G allele in cMPN patients and to verify its role in
the development of these diseases in a Brazilian population.
& METHODS
The study was submitted to and approved by the local
ethics committee. All of the participants signed an informed
consent. Blood and oral swab samples were collected from
56 patients who received treatment at one of two regional
oncologic services (Hospital do Caˆncer de Maringa´ and
Instituto do Caˆncer de Londrina); these patients were
previously diagnosed with BCR-ABL-negative cMPN
according to the 2008 WHO diagnostic criteria (1). Blood
samples were also collected from 90 healthy individuals
(blood donors from the Hemocentro Regional de Maringa´)
and used as controls, as the JAK2 V617F mutation is not
found in healthy individuals (3-6,13,14). DNA was extracted
from the biological specimens using a commercial kit
according to the recommendations of the manufacturer
(QIAampH DNA Blood Mini Kit, Qiagen).
All of the blood samples obtained from the cMPN
patients were genotyped for the JAK2 V617F mutation
using a PCR-RFLP assay as previously described (14). To
better visualize the post-digestion bands, we modified the
described technique to include 2 U (1 mL) of BsaXI enzyme
in each PCR amplicon digestion and used a 3% agarose gel
to run the post-digestion electrophoresis. The JAK2 V617F-
Figure 1 - JAK2 V617F screening using the PCR-RFLP technique. After digestion, the JAK2 V617F-positive samples presented a 460-bp
band relative to a 50-bp molecular weight ladder. (A) An ET JAK2 V617F negative patient. (B) A PV JAK2 V617F positive patient. (C) A
JAK2 V617F positive control. (D) A JAK2 V617F negative control. (E) Blank.
Figure 2 - JAK2 rs10974944 SNP allele screening using the PCR-RFLP technique. The presence of the G allele is characterized by the
observation of a 213-bp band, whereas the presence of the C allele is noted by the observation of a 176-bp band, relative to a 50-bp
molecular weight ladder. Lanes A-D represent patient blood samples. (A) Homozygous C allele. (B) Heterozygous C/G alleles.
(C) Homozygous G allele. (D) Heterozygous C/G alleles.
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positive samples presented a 460-bp band (Figure 1). The
JAK2 V617F-negative samples contained two bands: 241 bp
and 189 bp. The absolute and relative frequencies of the
JAK2 V617F mutation in the cMPN patients were calculated.
Considering the possibility that a loss of heterozygosity
occurred due to uniparental disomy, leading to a misinter-
pretation of the haplotype results, germline haplotypes
(determined by oral swab) were compared to the results of
the blood samples from the cMPN patients. Blood and oral
swab samples obtained from cMPN patients and blood
samples obtained from healthy subjects were submitted to
JAK2 rs10974944 SNP screening using a PCR-RFLP assay
developed by Trifa et al. (15,16). After digestion with the
MboI enzyme, the presence of the G allele was detected by
the observation of a 213-bp band, whereas the presence of
the C allele is noted by the observation of a 176-bp band
(Figure 2).
The allelic and genotypic frequencies were calculated
using direct counts. The allelic and genotypic frequencies
for the patients and the controls were compared using a
Chi-Square test with Yates’ correction, considering a 95%
confidence interval (CI).
& RESULTS
The overall characteristics of the cMPN patients enrolled
in this study are shown in Table 1. After analyzing each of
the cMPN patients alone, 16 (94%) of the 17 PV patients, 14
(64%) of the 22 ET patients and 7 (58%) of the 12 MF patients
were positive for the JAK2 V617F mutation. Five (10% of 56)
patients could not be classified with one of the three disease
variants and were therefore classified as myeloproliferative
neoplasms, unclassifiable (MPNu) according to the 2008
WHO diagnostic criteria (1). Some of those patients lacked
information in their medical records or clinical history, and
this missing data could have compromised the accuracy of
the classification. The JAK2 V617F mutation screening in
those patients indicated 80% (four of the five MPNu
patients) positive results, which suggested that they should
be placed into the BCR-ABL-negative cMPN group.
The distribution of JAK2 rs10974944 SNP genotypes and
alleles is shown in Table 2, according to JAK2 V617F
mutational status.
When comparing the JAK2 rs10974944 SNP genotypes
and allelic frequencies between the patients and controls
(Table 3), higher frequencies of the GG genotype and G
allele were observed in the cMPN patients (p= 0.0116;
OR = 3.079; 95% CI = 1.34727.04 and p= 0.0001; OR = 2.674;
95% CI = 1.63024.385, respectively). The CC genotype and C
allele were observed more frequently in the healthy controls
(p= 0.0029; OR = 0.331; 95% CI = 0.16420.666 and p= 0.0001;
OR = 0.374; 95% CI = 0.22820.614, respectively).
A significant association was also observed between the
JAK2 V617F mutation and the JAK2 rs10974944 SNP
genotype or allele after comparing the patients who carried
the mutation with the controls (Table 4). The GG genotype
and G allele were more frequently observed in the patients
who carried the mutation than in the healthy controls
(p= 0.006; OR = 3.482; 95% CI = 1.45428.339 and p= 0.0001;
OR = 3.222; 95% CI = 1.88425.510, respectively).
A comparison between the JAK2 rs10974944 SNP geno-
type or allele frequencies in the JAK2 V617F-negative
patients and in the controls revealed no significant
difference (data not shown). In addition, a comparison of
the JAK2 rs10974944 SNP genotype or allele frequencies
between the JAK2 V617F positive and negative patients did
not reveal a significant difference in contrast to what has
been previously described (11,12,16). This distinction may
be explained by the modest number of patients enrolled in
this study.
& DISCUSSION
Recent reports have suggested that hereditary genetic
factors, specifically the JAK2 haplotypes, can strongly
contribute to the development of cMPN (11,12,16-18).
These observations help explain previously known cMPN
family clusters (8,9).
Table 1 - General characteristics and JAK2 V617F
mutational status of the cMPN patients.
Age (median range, in years) 22-83 (60.6)
Sex
Male 25 (45%)
Female 31 (55%)
M:F 0.8:1
Diagnosis
PV 17 (30%)
JAK2 V617F-positive 16 (94%)
JAK2 V617F-negative 1 (6%)
ET 22 (39%)
JAK2 V617F-positive 14 (64%)
JAK2 V617F-negative 8 (36%)
MF 12 (21%)
JAK2 V617F-positive 7 (58%)
JAK2 V617F-negative 5 (42%)
MPNu 5 (10%)
JAK2 V617F-positive 4 (80%)
JAK2 V617F-negative 1 (20%)
TOTAL (cMPN patients) 56
cMPN: chronic myeloproliferative neoplasms; PV: polycythemia vera; ET:
essential thrombocytosis; MF: primary myelofibrosis; MPNu:
myeloproliferative neoplasms, unclassifiable
Table 2 - JAK2 rs10974944 SNP genotype/allele frequencies in cMPN patients and controls.
JAK2rs10974944 genotype/alleles cMPN patients Controls (n = 90)
JAK2 V617F-positive (n= 43) JAK2 V617F-negative (n= 13) Total (n = 56)
Genotype
CC 11 (26%) 7 (54%) 18 (32%) 53 (59%)
CG 17 (40%) 3 (23%) 20 (36%) 25 (28%)
GG 15 (34%) 3 (23%) 18 (32%) 12 (13%)
Allele
C 39 (45%) 17 (65%) 56 (50%) 131 (73%)
G 47 (55%) 9 (35%) 56 (50%) 49 (27%)
cMPN: chronic myeloproliferative neoplasms, SNP: single-nucleotide polymorphism
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The aim of this study was to analyze whether the genetic
factors described above also play an important role in the
development of cMPN in our population. The results of our
study corroborate the hypothesis that JAK2 haplotypes are a
major predisposing factor toward cMPN in the studied
population. The GG genotype and G allele frequencies,
representative of the JAK2 46/1 haplotype, were found to be
significantly higher in our sample of patients.
It was observed that the JAK2 V617F mutation could
occur in a homozygous or heterozygous fashion in the
affected hematopoietic cells (2-5). Homozygosity frequently
occurs for a specific allele through duplication of the
mutated allele and consequent loss of the non-mutated
allele (2). This event is called uniparental disomy. To rule
out acquired uniparental disomy as a misleading factor in
the genotype and allelic frequencies estimation, we ana-
lyzed oral swabs (data not shown) and verified that these
results were concordant with the blood sample results.
The correlation between the JAK2 46/1 haplotype and the
presence of the JAK2 V617F mutation has been well
documented (11,12). Recent studies evaluating this correla-
tion among other populations have also confirmed the JAK2
46/1 haplotype as a predisposing factor across various
ethnic groups (19-20).
It was suggested that the JAK2 46/1 haplotype brings
genetic instability to the JAK2 gene, favoring the emergence
of JAK2 acquired mutations, such as the JAK2 V617F and
JAK2 exon 12 mutations (10-12,18). Our data reinforces
these findings because the G allele and the GG genotype
were more frequent in the patients who carried the JAK2
V617F mutation than in the healthy controls.
As shown in Table 1, the characteristics of the studied
patients are very similar to those observed in the literature
(2-5), which indicates the comparability of our data and
supports the assertion that the presence of the G allele is a
pivotal factor in the development of cMPN in our
population.
Various hypotheses have been proposed to explain the
correlation between particular JAK2 haplotypes and the
risk of cMPN. As mentioned above, one hypothesis is that a
genetic instability brought by the presence of a specific
inherited haplotype facilitated the emergence of an
acquired JAK2 mutation (10-12,18). Another hypothesis
suggests that the JAK2 46/1 haplotype could confer a
proliferative or survival advantage to the neoplastic clone,
which may explain the increased frequency of the JAK2
46/1 haplotype in different populations of cMPN patients
(18). It is also possible that the various JAK2 haplotypes
could produce different intensities of intracellular signal-
ing, conferring the proliferative or survival advantage
mentioned above (11,12). These hypotheses might co-
exist or even act synergistically in the process of cMPN
oncogenesis.
The JAK2 V617F mutation also seems to play a role in
other myeloproliferative and myelodysplastic diseases,
reinforcing the importance of intracellular signaling path-
ways in the progression of disease (21).
The evaluation of genetic factors implicated in the
development of chronic myeloproliferative disorders helps
to identify acquired mutations, such as JAK2 V617F, and
allows for the development of diagnostic assays. Recently,
these molecular assays became a valuable tool in the
evaluation of patients presenting with polycythemias,
making diagnostic workup easier. In recently published
data, inherited genetic factors were suggested to be
important characters in the pathways of cMPN oncogenesis.
More studies are needed to clarify the exact role these
genetic factors play in modifying intracellular signaling and
Table 3 - Correlation between JAK2 rs10974944 SNP genotype/allele frequencies and the presence of cMPN (cMPN
patients vs. control group).
JAK2rs10974944 genotype/alleles cMPN patients vs. control group
Patients (n = 56) Controls (n = 90) OR (95% CI) p-value
Genotype
CC 18 (32%) 53 (59%) 0.331 (0.164-0.666) 0.0029
CG 20 (36%) 25 (28%) 1.44 (0.706-2.953) 0.4
GG 18 (32%) 12 (13%) 3.079 (1.347-7.04) 0.0116
Allele
C 56 (50%) 131 (73%) 0.374 (0.228-0.614) 0.0001
G 56 (50%) 49 (27%) 2.674 (1.630-4.385) 0.0001
cMPN: chronic myeloproliferative neoplasms, SNP: single nucleotide polymorphism.
Table 4 - Correlation between JAK2 rs10974944 SNP genotype/allele frequencies and the presence of the JAK2 V167F
mutation (JAK2 V617F-positive patients vs. control group).
JAK2rs10974944 genotype/alleles JAK2 V617F-positive patients vs. control group
JAK2 V617F-positive patients (n = 43) Controls (n = 90) OR (95% CI) p-value
Genotype
CC 11 (26%) 53 (59%) 0.24 (0.108-0.536) 0.0006
CG 17 (40%) 25 (28%) 1.7 (0.790-3.656) 0.244
GG 15 (34%) 12 (13%) 3.482 (1.454-8.339) 0.0078
Allele
C 39 (45%) 131 (73%) 0.311 (0.182-0.531) 0.0001
G 47 (55%) 49 (27%) 3.222 (1.884-5.510) 0.0001
cMPN: chronic myeloproliferative neoplasms, SNP: single-nucleotide polymorphism.
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perhaps to identify new targets for future diagnostic tools or
even therapeutic agents.
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